Barings Corporate Investors (MCI)

Barings Corporate Investors: Best In Class, Now Priced To Buy Again

Barings Corporate Investors Reports Preliminary Second Quarter 2026 Results and Announces Quarterly Cash Dividend Of $0.40 Per Share

PL Gold Mine Restart Update High Grade Gold Results, Resource Expansion Potential and Operational Readiness Update

Why This 15.3%-Paying CEF Is Making Big Changes

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat

MCI: Easing Share Price Leads To Premium Decline; This Could Be The Reason

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

MCI: Interest Rate Hikes Can Negatively Impact Performance

How To Invest For Secure Retirement With Big Dividends, 5.7% Yield